Connor, Clark & Lunn Investment Management Ltd. Poseida Therapeutics, Inc. Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $21.8 Billion
- Q1 2024
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Poseida Therapeutics, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 503,760 shares of PSTX stock, worth $1.47 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
503,760
Previous 374,522
34.51%
Holding current value
$1.47 Million
Previous $1.26 Million
27.66%
% of portfolio
0.01%
Previous 0.01%
Shares
4 transactions
Others Institutions Holding PSTX
# of Institutions
93Shares Held
38.1MCall Options Held
255KPut Options Held
62K-
Pentwater Capital Management LP Naples, FL5.98MShares$17.4 Million0.2% of portfolio
-
Black Rock Inc. New York, NY4.95MShares$14.5 Million0.0% of portfolio
-
Boxer Capital, LLC San Diego, CA4.48MShares$13.1 Million0.74% of portfolio
-
Silverarc Capital Management, LLC3.6MShares$10.5 Million3.85% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.37MShares$9.85 Million0.0% of portfolio
About Poseida Therapeutics, Inc.
- Ticker PSTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 85,775,600
- Market Cap $250M
- Description
- Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant ...